Elixiron Immunotherapeutics attracts $27m
Elixiron Immunotherapeutics Inc, a developer of therapeutics for cancer, neurological diseases and inflammatory disorders, has closed its Series A-1 funding round at $27 million.
23 August 2021•1 min read
Elixiron Immunotherapeutics Inc, a developer of therapeutics for cancer, neurological diseases and inflammatory disorders, has closed its Series A-1 funding round at $27 million.
AI agents drive new cybersecurity investment strategies
4 November 2026 · 10 mins read
LPs press emerging VCs on quality of their networks
3 November 2026 · 3 mins read
Download the November/December 2026 issue of Venture Capital Journal
2 November 2026 · 1 min read
Bites raises $40m Series A round to expand frontline worker learning platform
29 October 2026 · 7 mins read
OCIO Cerity seeks proof of exits as clients raise bar for venture funds
29 October 2026 · 4 mins read
Matter taps LPs that bring more than money for oversubscribed Fund II
28 October 2026 · 5 mins read
BackingMinds raises €50m for Fund III, focused on Nordic start-ups
26 October 2026 · 3 mins read
